Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to test if a combination treatment of nivolumab and
relatlimab will result in tumor reduction in patients with metastatic uveal melanoma.